SCRIBE
The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) - Checklist
This is a list of 26 items that should be included in research reports of single-case designs (or similar designs with very few participants).
Before submitting their manuscript, authors should use this checklist to ensure that they include all the necessary information. It is recommended that each criterion be carefully reviewed and noted on which page of the manuscript it is reported (or if it does not apply to the research being presented).
Developed from: Robyn L. Tate, et al. (2016). The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) 2016 statement. Journal of School Psychology, 56, 133-142. https://doi.org/10.1016/j.jsp.2016.04.001
|
Item number |
Topic |
Item description |
Reported |
|
TITLE and ABSTRACT |
|||
|
1 |
Title |
Identify the research as a single-case experimental design in the title |
|
|
2 |
Credentials |
Summarize the research question, populalion, design, methods including in!ervention/s (independent variable/s) and target behavior/s and any other outcome/s (dependent variable/s), results, and conclusions |
|
|
INTRODUCTION |
|||
|
3 |
Scientific background |
Describe the scientific background to identify issue/s under analysis, current scientific knowledge, and gaps in that knowledge base |
|
|
4 |
Aims |
State the purpose/aims of the study, research question/s, and, if applicable, hypotheses |
|
|
METHOD |
|||
|
|||
|
5 |
Design |
ldemify the design (e.g., withdrawal/reversal, multiple-baseline, alternating-treatments, changing-criterion, some combination thereof, or adaptive design) and describe the phases and phase sequence (whether determined a priori or data-driven) and, if applicable, criteria for phase change |
|
|
6 |
Procedural changes |
Describe any procedural changes that occurred during the course of the investigation after the start of the study |
|
|
7 |
Replication |
Describe any planned replication |
|
|
8 |
Randomization |
State whether randomization was used, and if so, describe the randomization method and the elements of the study that were randomized |
|
|
9 |
Blinding |
State whether blinding/masking was used, and if so, describe who was blinded/masked |
|
|
|||
|
10 |
Selection criteria |
State the inclusion and exclusion criteria, if applicable, and the method of recruitment |
|
|
11 |
Participant characteristics |
For each participant, describe the demographic characteristics and clinical (or other) features relevant to the research question, such that anonymity is ensured |
|
|
|||
|
12 |
Setting |
Describe characteristics of the setting and location where the study was conducted |
|
|
|||
|
13 |
Ethics |
State whether ethics approval was obtained and indicate if and how informed consent and/or assent were obtained |
|
|
|||
|
14 |
Measures |
Operationally define all target behaviors and outcome measures, describe reliability and validity, state how they were selected, and how and when they were measured |
|
|
15 |
Equipment |
Clearly describe any equipment and/or materials (e.g., technological aids, biofeedback, computer programs, intervention manuals or other material resources) used to measure target behavior/s and other outcome/s or deliver the interventions |
|
|
|||
|
16 |
Intervention |
Describe the intervention and control condition in each phase, including how and when they were actually administered, with as much detail as possible to facilitate attempts at replication |
|
|
17 |
Procedural fidelity |
Describe how procedural fidelity was evaluated in each phase |
|
|
|||
|
18 |
Analyses |
Describe and justify all methods used to analyze data |
|
|
RESULTS |
|||
|
19 |
Sequence completed |
For each participant, report the sequence actually completed, including the number of trials for each session for each case. For participant/s who did not complete, state when they stopped and the reasons |
|
|
20 |
Outcomes and estimation |
For each participant, report results, including raw data, for each target behavior and other outcome/s |
|
|
21 |
Adverse events |
State whether or not any adverse events occurred for any participant and the phase in which they occurred |
|
|
DISCUSSION |
|||
|
22 |
Interpretation |
Summarize findings and interpret the results in the context of current evidence |
|
|
23 |
Limitations |
Discuss limitations, addressing sources of potential bias and imprecision |
|
|
24 |
Applicability |
Discuss applicability and implications of the study findings |
|
|
DOCUMENTATION |
|||
|
25 |
Protocol |
If available, state where a study protocol can be accessed |
|
|
26 |
Funding |
Identify source/s of funding and other support; describe the role of funders |
|